There is a vast practice of using antimalarial drugs, RAS inhibitors, serine protease inhibitors, inhibitors of the RNA-dependent RNA polymerase of the virus and immunosuppressants for the treatment of the severe form of COVID-19, which often occurs in patients with chronic diseases and older persons. Currently, the clinical efficacy of these drugs for COVID-19 has not been proven yet. Side effects of antimalarial drugs can worsen the condition of patients and increase the likelihood of death. Peptides, given their physiological mechanism of action, have virtually no side effects. Many of them are geroprotectors and can be used in patients with chronic diseases. Peptides may be able to prevent the development of the pathological process during COVID-19 by inhibiting SARS-CoV-2 virus proteins, thereby having immuno- and bronchoprotective effects on lung cells, and normalizing the state of the hemostasis system. Immunomodulators (RKDVY, EW, KE, AEDG), possessing a physiological mechanism of action at low concentrations, appear to be the most promising group among the peptides. They normalize the cytokines’ synthesis and have an anti-inflammatory effect, thereby preventing the development of disseminated intravascular coagulation, acute respiratory distress syndrome and multiple organ failure.

中文翻译：

---

肽：用于治疗 COVID-19 的前景

使用抗疟疾药物、RAS 抑制剂、丝氨酸蛋白酶抑制剂、病毒的 RNA 依赖性 RNA 聚合酶抑制剂和免疫抑制剂治疗重症 COVID-19 的实践很多，这通常发生在慢性病患者身上和老年人。目前，这些药物对 COVID-19 的临床疗效尚未得到证实。抗疟药的副作用会使患者的病情恶化并增加死亡的可能性。鉴于其生理作用机制，肽几乎没有副作用。其中许多是老年保护剂，可用于慢性病患者。肽可能能够通过抑制 SARS-CoV-2 病毒蛋白来阻止 COVID-19 病理过程的发展，从而对肺细胞具有免疫和支气管保护作用，并使止血系统的状态正常化。免疫调节剂（RKDVY、EW、KE、AEDG）在低浓度下具有生理作用机制，似乎是肽中最有前途的一类。它们使细胞因子的合成正常化并具有抗炎作用，从而防止弥散性血管内凝血、急性呼吸窘迫综合征和多器官衰竭的发展。